{"id":44642,"date":"2022-06-02T23:01:34","date_gmt":"2022-06-02T21:01:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"modified":"2022-06-02T23:01:34","modified_gmt":"2022-06-02T21:01:34","slug":"precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae<\/sup>-based ex vivo<\/i> allogeneic CAR T and in vivo<\/i> gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022, respectively (the \u201cGrant Dates\u201d), the Compensation Committee of Precision\u2019s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (\u201cInducement Award Plan\u201d). The inducement awards consist of options to purchase (\u201cstock options\u201d) an aggregate of 916,416 shares of Precision\u2019s common stock, par value $0.000005 (the \u201cCommon Stock\u201d) and 199,454 restricted stock units (\u201cRSUs\u201d) that represent a contingent right to receive one share of Common Stock. The stock options and RSUs were granted among two employees. Each of the stock options and the RSUs were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employees to commence service with Precision.\n<\/p>\n

<\/a><\/p>\n

\nThe stock options have a per share exercise price equal to the fair market value of Precision\u2019s Common Stock on the applicable grant date, which was equal to $1.68 on each of the Grant Dates. Each of the stock options has a 10-year term and vests (subject to continued service to Precision through the applicable vesting dates) as to 25% of the award on the first anniversary of the date of commencement of employment and, as to the remaining 75%, in substantially equal quarterly installments over the three years thereafter. The RSUs vest on the first anniversary of the date of commencement of employment (subject to continued service to Precision through the applicable vesting date).\n<\/p>\n

\nAbout Precision BioSciences, Inc.<\/b>\n<\/p>\n

\nPrecision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae<\/sup> genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company\u2019s pipeline consists of multiple ex vivo <\/i>\u201coff-the-shelf\u201d CAR T immunotherapy clinical candidates and several in vivo<\/i> gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Mei Burris
\n
Director, Investor Relations and Finance
\n
Mei.Burris@precisionbiosciences.com<\/a>\n<\/p>\n

\nMedia Contact:<\/b>
Maurissa Messier
\n
Senior Director, Corporate Communications
\n
Maurissa.Messier@precisionbiosciences.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022, respectively (the \u201cGrant Dates\u201d), the Compensation Committee of Precision\u2019s Board of Directors approved the grant of inducement … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44642","6":"format-standard","7":"category-industry"},"yoast_head":"\nPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022, respectively (the \u201cGrant Dates\u201d), the Compensation Committee of Precision\u2019s Board of Directors approved the grant of inducement ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T21:01:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2022-06-02T21:01:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":397,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005960\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005960\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"datePublished\":\"2022-06-02T21:01:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005960\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005960\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","og_description":"DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022, respectively (the \u201cGrant Dates\u201d), the Compensation Committee of Precision\u2019s Board of Directors approved the grant of inducement ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T21:01:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2022-06-02T21:01:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/"},"wordCount":397,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/","name":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg","datePublished":"2022-06-02T21:01:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220602005960\/en\/593587\/21\/Precision_BioSciences_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44642"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44642\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}